PAH News

Obese people with pulmonary arterial hypertension (PAH) are less likely than patients of normal weight to die while hospitalized, finds a study examining the so-called “obesity paradox.” The study, ... Read more

July 19, 2017July 19, 2017

Many Scleroderma Patients Progress Slowly Toward PAH, Four-year Study Indicates

News, PAH News

The exercise capacity of people with scleroderma who have yet to develop pulmonary arterial hypertension (PAH) diminishes over time, according to an Austrian study. Their lung function during exercise also ... Read more

July 17, 2017July 17, 2017

Arena Pharmaceuticals Announces Positive Results for Ralinepag in PAH Patients

News, PAH News

Arena Pharmaceuticals has announced positive results for ralinepag (APD811), an investigational prostacyclin receptor agonist being investigated in a Phase 2 trial to treat pulmonary arterial hypertension (PAH). Ralinepag is an oral ... Read more

July 12, 2017July 12, 2017

Extended Release Formulation of PAH Therapy Ralinepag Shows Promise in Phase 1 Trial

News, PAH News

Results of a Phase 1 clinical study in healthy volunteers evaluating different formulations of Arena Pharmaceuticals’ prostacyclin receptor agonist, ralinepag, for the treatment of pulmonary arterial hypertension (PAH), showed ... Read more

July 10, 2017July 10, 2017

Adipsin Protein Is a Biomarker of PAH Associated with Systemic Sclerosis, Study Finds

News, PAH News, PH News

Elevated levels of a protein called adipsin, produced by adipose or fat tissue, was found to be associated with an increased risk of pulmonary arterial hypertension (PAH) and associated cardiovascular ... Read more

July 7, 2017July 7, 2017

SteadyMed Submits New US Drug Application for PAH Treatment Trevyent

News, PAH News

SteadyMed Therapeutics submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Trevyent (treprostinil injection) in the treatment of pulmonary arterial hypertension (PAH), SteadyMed’s partner, Cardiome Pharma, recently announced. ... Read more

June 23, 2017June 23, 2017

Treprostinil-linked Adverse Events not Associated with Mortality in All PAH Patients

News, PAH News

Adverse drug events (ADEs) associated with subcutaneous treprostinil use for the treatment of pulmonary arterial hypertension (PAH) were found not to be associated with a higher mortality risk, except for ... Read more

June 21, 2017June 21, 2017

Johnson & Johnson Completes Acquisition of Actelion, a Leader in Pulmonary Hypertension Therapies

CTEPH News, News, PAH News, PH News

Johnson & Johnson has completed its acquisition of Actelion, a company that develops pulmonary hypertension therapies, six months after the deal was announced in January. Actelion is now part of J&J’s Janssen Pharmaceuticals ... Read more

June 16, 2017June 16, 2017

Remodulin Seen to Safety Treat Man with Severe PH, Chronic Kidney Disease in Case Study

News, PAH News

A subcutaneous infusion of Remodulin (treprostinil) was an effective and tolerable treatment against severe pulmonary hypertension associated with chronic kidney disease in a patient on hemodialysis, according to a case ... Read more

June 13, 2017June 27, 2017

Doctors Are Doing Inadequate Job of Screening Scleroderma Patients for PAH, Study Concludes

News, PAH News

Scientists have long known that people with scleroderma are at increased risk of developing pulmonary arterial hypertension. But many with scleroderma whom doctors suspect of having PAH are not receiving optimal screening ... Read more